Abstract: Disclosed are a method for preparing a series of novel pyridine derivatives and a use thereof. Such derivatives can be used in the treatment of related diseases caused by mycobacteria, in particular diseases caused by pathogenic mycobacteria, such as Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium avium and Mycobacterium marinum.
Abstract: The present invention relates to novel pyridino[1,2-?]pyrimidone compounds represented by formula (I) or pharmaceutically acceptable salts thereof; and a method of use thereof for treating tumors.
Type:
Grant
Filed:
June 16, 2015
Date of Patent:
January 16, 2018
Assignee:
CISEN PHARMACEUTICAL CO., LTD.
Inventors:
Huiping Guan, Chengde Wu, Tao Yu, Lei Huang, Dongling Hao, Bo Gao, Jikui Sun, Nengyang Shi, Shuhui Chen
Abstract: Provided in the present invention are a 2-arylbenzofuran-7-formamide compound as shown in general formula I or a pharmacologically or physiologically acceptable salt thereof, a preparation method thereof and use thereof in preparing anti-tumour drugs, wherein R1 and R2 are each independently hydrogen, straight or branched chained C1-C4 alkyl, C3-C4 cycloalkyl or saturated 5- or 6-membered heterocyclyl containing oxygen or nitrogen; or R1 and R2 together with N form an unsubstituted or substituted saturated 5- or 6-membered heterocyclyl containing at least one heteroatom, wherein the heteroatom is O, N and S, the substituent is a methyl on N; R3 is a hydrogen atom or a chlorine atom; R4 is a hydrogen atom or a fluorine atom; X is CH, CF or N; and Y is CH, CF or N.
Type:
Grant
Filed:
January 14, 2013
Date of Patent:
January 3, 2017
Assignees:
SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, CISEN PHARMACEUTICAL CO., LTD.
Inventors:
Chunhao Yang, Zehong Miao, Jian Ding, Meng Wang, Jinxue He, Cun Tan, Yi Chen
Abstract: Disclosed are new thienyl [3,2-d] pyrimidin-4-one compounds shown as the general formula (I), preparation method, pharmaceutical compositions and pharmacological use thereof. The compounds are strong DPPIV (dipeptide peptidase IV) inhibitors and can treat type II diabetes through well inhibiting DPPIV indirectly increasing the content of GLP-1 in vivo and inducing a series of physiological actions in vivo. Therefore, the compounds could be developed as new promising drugs for treating diabetes.
Type:
Grant
Filed:
October 23, 2012
Date of Patent:
June 2, 2015
Assignees:
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Cisen Pharmaceutical Co., Ltd.
Inventors:
Hong Liu, Jia Li, Jian Li, Jingya Li, Jiang Wang, Mingbo Su, Jie Lian, Hualiang Jiang, Kaixian Chen